BioSpace News Archive

Today, the U.S. Food and Drug Administration approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use for the emergency treatment of known or suspected opioid overdose.

Allurion Technologies, Inc. and Compute Health Acquisition Corp. announced that Compute Health’s stockholders have approved all proposals related to the previously announced business combination between Compute Health and Allurion at a special meeting of Compute Health’s stockholders held on July 28, 2023.

OKYO Pharma Limited announced that it received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying OKYO that, for the previous 30 consecutive business days, the market value of OKYO’s ordinary shares had closed below the minimum $35 million requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550.

Navidea Biopharmaceuticals, Inc. received written notification from NYSE American LLC stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. — ticker symbol NAVB —from the Exchange.

Merck announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Augmedix today announced it will report financial results for the second quarter ended June 30, 2023, on Monday, August 7, 2023, after the market closes.

Revive Therapeutics Ltd. today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent.”

Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites.

Intra-Cellular Therapies, Inc. today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 3, 2023, to provide a corporate update and discuss details of the Company’s financial results for the quarter ended June 30, 2023.